<DOC>
	<DOCNO>NCT00657553</DOCNO>
	<brief_summary>To evaluate whether use drug bortezomib start remission prevent relapse long period time .</brief_summary>
	<brief_title>Preemptive Strike With Bortezomib Multiple Myeloma Patients</brief_title>
	<detailed_description>Although advance treatment multiple myeloma lead improved remission rate , risk serious relapse high . The drug Bortezomib highly effective treatment disease advance stage post-transplant relapse . Due need maintenance therapy , necessary look certain drug may prolong remission increase quality life . Bortezomib , take begin remission , may prove beneficial maintenance drug management multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosed multiple myeloma currently previously enrol UARK 98026 currently eventfree time evaluation . Performance status 02 base SWOG criterion Previously document platelet count &gt; 75,000/ul within 35 day prior enrollment Previously document peripheral absolute neutrophil count &gt; 1,000/ul within 35 day prior enrollment . Adequate renal function Signed informed consent Female subject postmenopausal willing use acceptable birth control Male subject agree use acceptable method contraceptive Hypersensitivity Bortezomib , boron , mannitol Female subject pregnant breastfeeding Experienced myocardial infraction within 6 month prior enrollment Received investigational new drug within 14 day enrollment Received antimyeloma therapy within 14 day Serious medical psychiatric illness likely interfere participation clinical study Diagnosed treat another malignancy within 3 year enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>